Lung Carcinoma — Trials

Lung Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

7,791 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 2,130
Recruiting: 1,129
Ph III recruiting: 164
Growth YoY: +1.2%
Industry share: 43%
Top sponsor: National Cancer Institute (NCI)
Termination share: 38.6%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,177)

clinicaltrialsPublishedShowing 151–200 of 2,054 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07079475	Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)	recruiting	Phase 1 / Phase 2	220	Dizal PharmaceuticalsINDUSTRY	1	Aug 31, 2026	clinicaltrials
NCT04449874	A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation	active not recruiting	Phase 1	498	Genentech, Inc.INDUSTRY	17	Aug 28, 2026